Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for AbbVie Inc. (NYSE: ABBV), a pharmaceutical preparation manufacturing company focused on immunology, oncology, neuroscience, eye care and its Allergan Aesthetics portfolio. AbbVie’s filings provide structured insight into its financial condition, capital structure, research spending and key corporate events.
Recent Form 8‑K filings discuss items under “Results of Operations and Financial Condition,” including guidance for specific quarters and full‑year periods and the impact of acquired in‑process research and development (IPR&D) and milestones expense on diluted earnings per share. Other 8‑K disclosures describe settlements of litigation related to generic manufacturers of upadacitinib tablets (marketed as RINVOQ) and note that AbbVie’s common stock and multiple series of senior notes are registered and listed on the New York Stock Exchange.
Through this filings feed, users can access AbbVie’s current reports alongside its periodic reports when available, such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q. These documents typically contain details on research and development activities, manufacturing investments, and the performance of key therapeutic areas, as well as discussions of risk factors and capital allocation. For a company active in oncology and other complex therapeutic fields, these filings help explain how collaborations, licensing agreements and acquisitions are reflected in financial statements, particularly through acquired IPR&D and milestones expense.
Stock Titan enhances these filings with AI-powered summaries that highlight important sections, such as earnings guidance updates, litigation disclosures and changes in capital structure. Users can quickly see how items like AbbVie’s guidance revisions, settlement agreements or investment commitments appear in official SEC documents. Real-time updates from EDGAR, combined with AI explanations of forms such as 8‑K and, where applicable, 10‑K, 10‑Q and Form 4 insider transaction reports, allow investors and researchers to review ABBV’s regulatory record more efficiently and understand the context behind headline numbers and corporate announcements.
AbbVie reported first‑quarter 2026 results with solid revenue growth but lower earnings. Net revenues rose to $15.0 billion, up 12% year over year, driven by strong expansion of immunology drugs Skyrizi and Rinvoq, neuroscience brands like Vraylar, Botox Therapeutic, Ubrelvy and Qulipta, and aesthetics products including Botox Cosmetic.
Operating earnings increased to $4.0 billion, but net earnings attributable to AbbVie fell to $695 million and diluted EPS to $0.39, mainly due to a $2.4 billion non‑cash increase in contingent consideration liabilities and $744 million of acquired R&D and milestone expense, including a $650 million upfront payment to RemeGen.
AbbVie generated strong operating cash flow of $3.8 billion, raised $8.0 billion through new senior notes, paid $3.1 billion in dividends and repurchased $1.1 billion of stock. The company highlighted a large late‑stage pipeline, new regulatory filings for Skyrizi and Rinvoq, and a voluntary U.S. pricing agreement alongside major planned U.S. manufacturing investments.
AbbVie Inc ownership filing: Vanguard Capital Management reports 132,924,058 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 132,924,058 shares and sole voting power for 18,043,734 shares. The disclosure notes these holdings include securities held for Vanguard funds and managed accounts and identifies affiliated business units that exercise voting or dispositive power on behalf of clients.
AbbVie reported strong first-quarter 2026 results, with worldwide net revenues of $15.002 billion, up 12.4% year over year on a reported basis (10.3% operational). Growth was driven by immunology and neuroscience, while oncology was flat and aesthetics grew modestly.
Immunology net revenues were $7.290 billion, up 16.4%, led by Skyrizi at $4.483 billion and Rinvoq at $2.119 billion, which more than offset a 38.6% decline in Humira to $688 million. Neuroscience net revenues rose 26.0% to $2.875 billion, with Botox Therapeutic at $1.009 billion and combined Ubrelvy/Qulipta at $635 million.
On a GAAP basis, diluted EPS was $0.39, down 45.8%, while adjusted diluted EPS rose 7.7% to $2.65, including an unfavorable $0.41 per-share impact from acquired IPR&D and milestones expense. AbbVie raised its full-year 2026 adjusted EPS guidance to a range of $14.08–$14.28.
AbbVie Inc. updated its 2026 earnings guidance to reflect a sizeable first-quarter charge for acquired in-process R&D and milestones. The company expects to record $744 million of pre-tax acquired IPR&D and milestones expense in the first quarter of 2026, which is estimated to reduce both GAAP and adjusted diluted earnings per share by $0.41.
Including this impact, AbbVie now guides full-year 2026 adjusted diluted EPS to a range of $13.96 to $14.16, compared with prior guidance that excluded this expense. First-quarter 2026 adjusted diluted EPS guidance, including the charge, is $2.56 to $2.60, down from the previously announced range of $2.97 to $3.01 that did not include the IPR&D and milestones expense.
Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of 71 stock equivalent units tied to AbbVie common stock at a reference value of $217.49 per unit. Following this grant, her balance in these units increased to 784 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are generally paid in cash at around age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the balance also reflects units accumulated through a dividend reinvestment feature.
RAPP EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Edward J. Rapp received a grant of 155 Stock Equivalent Units on March 31, 2026. The units were credited as director fees at a reference price of $217.49 per unit and are linked to AbbVie common stock performance.
Following this grant, Rapp holds a reported total of 28,865 Stock Equivalent Units. These units are maintained in a grantor trust established by the director and are generally paid in cash at age 65 or upon retirement from the board, with value tracking AbbVie stock, including a dividend reinvestment feature.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Robert J. Alpern received a grant of 35 stock equivalent units tied to AbbVie common stock as director compensation. The units were credited on the basis of director fees at a reference value of $217.49 per unit and track the return of AbbVie shares.
Following this award, Alpern’s balance increased to 10,369 stock equivalent units held in grantor trust accounts. These units are payable in cash, generally at age 65 or when he retires from the AbbVie board, and the balance also reflects units added through a dividend reinvestment feature.
The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
AbbVie Inc. has released its 2026 proxy statement for the May 8, 2026 virtual annual meeting, asking stockholders to elect four Class II directors, ratify Ernst & Young as auditor, approve executive pay on an advisory basis, and back a management proposal to eliminate supermajority voting. The board recommends voting against a stockholder proposal seeking an independent board chair.
The proxy highlights 2025 total net revenues of $61.2BN, growth platform net revenues of $56.6BN, and operating cash flow of $19.0BN, along with 12 blockbuster products and about 90 active clinical and device programs. Over the last decade, AbbVie reports a market capitalization increase of $309BN, quarterly dividend growth from $0.57 to $1.73 per share, and total stockholder return of +485%, outpacing the S&P 500 and NYSE Arca Pharmaceutical Index.
The board emphasizes strong governance and ESG practices, including a majority-independent board with a lead independent director, clawback, anti-hedging and anti-pledging policies, and proxy access. Executive pay is described as heavily performance-based, with more than three-fourths of named executive officer compensation tied to non-GAAP financial, strategic, and long-term equity incentives aligned with stockholder returns.